Tagged with Global

Global Over the past 12 months, PharmaBoardroom has spoken to the heads of several key regulatory bodies across the world. While the approval processes for COVID-19 vaccines have evidently been top of their priority lists, other key topics discussed included the potential of data and AI to change the drug approval…

USA In his latest PharmaBoardroom piece, John Singer looks at Biogen’s marketing campaign for its new Alzheimer’s drug, extending and linking the controversy to the grander strategic themes reshaping the ‘drug market’ as a whole, including the impact of the internet on cognitive change, the unmet need for a different premise for…

Global PharmaBoardroom has spread its wings far and wide in 2021 (albeit digitally!), from well covered markets such as Singapore and Switzerland to new frontiers like Saudi Arabia. Our interviewees have ranged from regional Big Pharma and medtech general managers, to the CEOs of important local players, and the heads of…

Global As our thoughts here at PharmaBoardroom turn towards the summer holidays, we are happy to share the five most-read articles from our global contributor network so far in 2021. These thought leadership pieces cover topics as vital and diverse as the latest regulatory updates from China; EU-UK pharma trade; the…

USA Patient advocate and regular PharmaBoardroom contributor Monica Weldon examines how healthcare’s data revolution has thus far largely ignored the patient voice and argues for a more inclusive approach to drive better, fairer outcomes.    It is natural to want to be healthy, have healthy children, have the best quality of…

Global Cancer is one of the most frightening words in any language but is especially heart-wrenching when it comes to children. João de Bragança, President of Childhood Cancer International (CCI) and Nicole Scobie, President of Zoé4life and CCI European Board Member, share CCI’s aims as the largest parent-led international organisation supporting…

USA With the US FDA’s controversial recent decision to approve Biogen and Eisai’s aducanumab – the first approval for a new Alzheimer’s disease (AD) drug since 2003 – PharmaBoardroom has raided its archives to bring key industry stakeholders’ takes on the significance of this decision and what it might mean for…

Global Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland outlines how AI has already begun to transform pharmaceutical strategy and highlights five ways in which it can be better utilised in pricing and market access decision making.   Artificial intelligence (AI) has been creating a buzz in…

Global Big Pharma’s representatives are warning of upcoming bottlenecks in the COVID-19 vaccine manufacturing supply chain and are asking for a unified approach to address inefficiencies and increase manufacturing capacities. However, recently published reports and news point to inefficiencies within the manufacturing industry itself and not necessarily a lack of raw…

Global The issue of COVID-19 vaccine access in developing nations has thrust intellectual property (IP) into global headlines. Against the backdrop of heated arguments both for and against an IP waiver for COVID-related products, the global pharma industry has launched a new initiative on IP, asserting its crucial importance to continued…

USA The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the day after that, another two percent. However, the Massachusetts-based company’s CEO Stephane Bancel remains unconcerned and believes that their successful vaccine is just the beginning of the mRNA era…

Global On World Intellectual Property (IP) Day 2021, the innovative biopharmaceutical industry came together to launch a new initiative foregrounding the benefits to patients and to society at large of a robust IP framework. Under the INTERPAT umbrella, 25 industry members and associations launched the ‘IP Principles for Advancing Cures and…